Syndax Pharmaceuticals, Inc. (SNDX)

Market Cap	1.34B
Revenue (ttm)	77.93M
Net Income (ttm)	-334.99M
Shares Out	86.14M
EPS (ttm)	-3.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,707,085
Open	16.42
Previous Close	16.37
Day's Range	15.53 - 16.50
52-Week Range	8.58 - 22.50
Beta	0.72
Analysts	Strong Buy
Price Target	38.40 (+146.95%)
Earnings Date	Nov 4, 2025

About SNDX

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combinati...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 3, 2016
• Employees: 270
• Stock Exchange: NASDAQ
• Ticker Symbol: SNDX
• Website: https://syndax.com

Analyst Summary

According to 10 analysts, the average rating for SNDX stock is "Strong Buy." The 12-month stock price target is $38.4, which is an increase of 146.95% from the latest price.

Price Target

$38.4

(146.95% upside)

Analyst Consensus: Strong Buy